Zai Lab Announces Upcoming Presentation at February Investor Conference
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced their participation in the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 8:40 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced their participation in the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 8:40 a.m. ET. This virtual investor conference will feature a fireside chat with company management.
Investors can access the live webcast and an archived replay for 90 days on Zai Lab's website under the “Events & Presentations” section. Zai Lab focuses on developing therapies for oncology, autoimmune disorders, infectious diseases, and neuroscience while building partnerships to enhance their global biopharmaceutical pipeline.
Details
News Market Reaction – ZLAB
The recorded move for ZLAB in the trading session of this news was -0.72%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following virtual investor conference in February:
11th Annual SVB Leerink Global Healthcare Conference
Fireside Chat: Thursday, February 17, 2022, 8:40 a.m. ET
Webcast link of the 11th Annual SVB Leerink Global Healthcare Conference will be available under “Events & Presentations” in the “Investor Relations” section of Zai Lab’s website. An archived replay will be available for 90 days following the event.
About Zai Lab
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is a patient-focused, innovative, commercial-stage, global biopharmaceutical company focused on developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. To that end, our experienced team has secured partnerships with leading global biopharmaceutical companies in order to generate a broad pipeline of innovative marketed products and product candidates. We have also built an in-house team with strong product discovery and translational research capabilities and are establishing a pipeline of proprietary product candidates with global rights. Our vision is to become a leading global biopharmaceutical company, discovering, developing, manufacturing and commercializing our portfolio in order to impact human health worldwide.
For additional information about the company, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.
For more information, please contact:
ZAI LAB CONTACTS:
Investor Relations: Ron Aldridge / Lina Zhang
+1 (781) 434-8465 / +86 136 8257 6943
ronald.aldridge@zailaboratory.com / lina.zhang@zailaboratory.com
Media: Danielle Halstrom / Xiaoyu Chen
+1 (215) 280-3898 / +86 185 0015 5011
danielle.halstrom@zailaboratory.com / xiaoyu.chen@zailaboratory.com
Zai Lab Limited
Source: Zai Lab Limited
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.